A Phase 1, Single Site, Open-Label Study to Assess the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Pegloticase (KRYSTEXXA) in Patients on Hemodialysis

Trial Profile

A Phase 1, Single Site, Open-Label Study to Assess the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Pegloticase (KRYSTEXXA) in Patients on Hemodialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Pegloticase (Primary)
  • Indications Gout
  • Focus Pharmacokinetics
  • Sponsors Savient Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2013 Data will be presented at the American Society of Nephrology (ASN) Kidney Week 2013, according to a Savient Pharmaceuticals media release.
    • 03 Oct 2013 Results will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2013 Annual Meeting according to a Savient Pharmaceuticals media release.
    • 19 Mar 2013 Status changed from recruiting to completed, as reported in a Savient Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top